Acusphere to Develop Potential Abraxane(R) Bioequivalent

Reformulation of paclitaxel offers partnership opportunities and 
faster track to commercialization 
WATERTOWN, Mass.--(BUSINESS WIRE)--November 02, 2007
Acusphere, Inc. (NASDAQ: ACUS) announced today that its product
candidate AI-850 has a comparable pharmocokinetic profile to the
breast cancer drug Abraxane(R) based upon human data available in
publications on each drug. AI-850 is Acusphere's patented formulation
of paclitaxel, the active ingredient in Abraxane. Drug product
candidates that are confirmed to have equivalent pharmacokinetics in a
human study may be eligible for regulatory approval as a
bioequivalent, with an accelerated development timeline, since Phase 2
and 3 human clinical trials are usually not required. Abraxane for
Injectable Suspension, which is marketed under a co-promotion
agreement between Abraxis BioScience, Inc. and AstraZeneca, generated
$150 million in revenues in the six months ended June 30, 2007, and is
projected by some analysts to reach revenues of $1 billion by 2013. 
Acusphere plans to make changes to the AI-850 formulation that
will make it a more suitable commercial formulation and plans to work
with a partner to bring this improved formulation into development for
approval as a bioequivalent to Abraxane. The Company has commenced
discussions with potential partners to move this program forward. 
Sherri C. Oberg, Acusphere's President and CEO, said, "Our
Hydrophobic Drug Delivery System (HDDS) technology has enabled us to
engineer a drug candidate that has comparable pharmacokinetics to one
of the fastest growing cancer drugs. We are in active discussions with
potential partners on a strategy that could lead to quicker
commercialization options for this important program. This program
will have no impact on our previously-communicated financial guidance
for operating expenses." 
About Acusphere, Inc. 
Acusphere is a specialty pharmaceutical company that develops new
drugs and improved formulations of existing drugs using its
proprietary microsphere technology. We are focused on developing
proprietary drugs that can offer significant benefits such as improved
safety and efficacy, increased patient compliance, greater ease of
use, expanded indications or reduced cost. Our lead product candidate,
Imagify(TM) (Perflubutane Polymer Microspheres) for Injectable
Suspension, is a cardiovascular drug for the detection of coronary
artery disease, the leading cause of death in the United States. In
May 2007 we announced the results of our Phase 3 pivotal trials for
Imagify. We are currently working towards submitting an NDA (New Drug
Application) for Imagify. Imagify is designed to enable ultrasound to
compete more effectively with nuclear stress testing, the leading
procedure for detecting coronary artery disease. It is estimated that
over 10 million procedures are done each year in the U.S. to detect
coronary artery disease, the leading cause of death in the United
States. Imagify and the Company's other product candidates were
created using proprietary technology that enables Acusphere to control
the porosity and size of nanoparticles and microspheres in a versatile
manner that allows them to be customized to address the delivery needs
of a variety of drugs. For more information about Acusphere visit the
Company's web site at www.acusphere.com. 
"Acusphere" and "Imagify" are trademarks of Acusphere, Inc. 
The above press release contains forward-looking statements, which
are made pursuant to the safe harbor provisions of Section 21E of the
Securities Exchange Act of 1934, including statements regarding the
commercial opportunity for AI-850 and Imagify, statements regarding
the timing and likelihood of regulatory approval, and the commercial
prospects for, each of these product candidates and statements
regarding partnership discussions. There can be no assurance that
these partnership discussions will result in an agreement. 
There can be no assurance that the FDA will accept the Company's
NDA for Imagify or that Imagify will be approved for the indication
the Company is seeking, or at all. The Company's actual results may
differ materially from those anticipated in these forward-looking
statements based upon a number of factors, including anticipated
operating losses and existing capital obligations, uncertainties
associated with research, development, testing and related regulatory
approvals, including uncertainties regarding regulatory evaluation of
the Company's statistical analysis plan and clinical trial results
with respect to Imagify and uncertainties regarding the potential
affects of not achieving clinical endpoints, limited time to date for
the Company to review the details of the clinical trial results,
future capital needs and uncertainty of additional financing,
uncertainties regarding the cost, timing and ultimate success of the
qualification of the Company's commercial manufacturing facility in
accordance with applicable regulatory requirements, complex
manufacturing, high quality requirements, lack of commercial
manufacturing experience, dependence on third-party manufacturers,
suppliers and collaborators, uncertainties associated with
intellectual property, competition, loss of key personnel,
uncertainties associated with market acceptance and adequacy of
reimbursement, technological change and government regulation, and
other risks and challenges detailed in the Company's filings with the
U.S. Securities and Exchange Commission, including the Company's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.
Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
press release. The Company undertakes no obligation to publicly
release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances that
occur after the date of this press release or to reflect the
occurrence of unanticipated events. 
Abraxane(R) is a registered trademark of Abraxis BioScience Inc. 
CONTACT:
Conway Communications
Mary T. Conway, 617-244-9682
or
Acusphere, Inc.
Investors: 617-925-3444
IR@acusphere.com
or
Media: 617-648-8800
 
 
Press spacebar to pause and continue. Press esc to stop.